Société des Produits Nestlé (SPN)
Trial Pipeline
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
NCT06347315
Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia
NCT04877366
A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.
NCT04639726
Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula
NCT03236207
Tolerance of a Calorically Dense Enteral Nutrition Formula
NCT02806427
Feeding Tolerance Evaluation
NCT02405572
Probiotic Formula and Infant Growth
NCT01476397
Feeding Trial in Pediatric Patients
NCT01469117
Validation of a Nutrition Screening Tool
NCT01473706
Assessment of Growth of Infants Fed a New Formula
NCT00937014
Dose-response Enteral Citrulline for Normal Healthy Volunteers and Surgery Patients
NCT00950976
Therapeutic Areas
What the Pipeline for Société des Produits Nestlé (SPN) Shows
According to the ClinicalTrials.gov registry, Société des Produits Nestlé (SPN) is linked to 11 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 9% of the sponsor's indexed portfolio — and 10 are already marked complete, representing roughly 91% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Société des Produits Nestlé (SPN) reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Société des Produits Nestlé (SPN) is Dietary Supplement with 2 linked trials, and 8 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.